Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Kodak's $765 million manufacturing loan on the rocks as red flags multiply
CVS, Salesforce team up to unite return-to-work platforms
Pfizer, Moderna and Gilead reputations climb on COVID-19 vaccine and treatment news, according to Harris Poll
Biopharma roundup: Slow enrollment slims Moderna's odds for a 2020 shot approval; Experts won't be fooled again on Inovio vaccine
Healthcare roundup: U.S. hits 5M confirmed COVID-19 cases
AbbVie infectious disease exec jumps ship to COVID antiviral biotech
Kaiser Permanente reports $4.5B in Q2 net income as COVID-19 drives down operating costs
PPD squeezes out a revenue growth despite COVID-19 disruption
GigaGen’s polyclonal antibody against COVID-19 outperforms plasma in lab tests

Featured Story

Kodak's $765 million manufacturing loan on the rocks as red flags multiply

By Kyle Blankenship

Eastman Kodak's unlikely deal with the federal government to dive into drug manufacturing has raised eyebrows, not only for the size of the loan itself but Kodak's lack of experience—and some executive stock option grants that preceded the announcement. Now, with investigations mounting, the U.S. is pumping the brakes.

CVS, Salesforce team up to unite return-to-work platforms

By Paige Minemyer

CVS Health and Salesforce are partnering to bring together their return-to-work platforms.

Pfizer, Moderna and Gilead reputations climb on COVID-19 vaccine and treatment news, according to Harris Poll

By Beth Snyder Bulik

The latest Harris Poll numbers on pharma reputations and COVID-19 vaccines and treatments finds that drugmakers in the news reaped hefty boosts to their image. The early August data show Pfizer, Gilead Sciences and Moderna trending positively with consumers who'd seen their news about treatments and vaccines.

Biopharma roundup: Slow enrollment slims Moderna's odds for a 2020 shot approval; Experts won't be fooled again on Inovio vaccine

By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner

Health experts think slow enrollment could push Moderna's phase 3 results into next year. Analysts cut through the hype for Inovio's COVID-19 shot. Russia took heat for plans to inoculate the public with an unapproved vaccine. Drugmakers doing COVID-19 work saw their public perception rise. Plus, PPD's revenue rose in Q2 on COVID-19 efforts.

Healthcare roundup: U.S. hits 5M confirmed COVID-19 cases

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

AbbVie infectious disease exec jumps ship to COVID antiviral biotech

By Ben Adams

AbbVie and Roche alum Janet Hammond, M.D., Ph.D., Sc.M., F.C.P. has nabbed the chief development officer role at infectious disease biotech Atea Pharmaceuticals.

Kaiser Permanente reports $4.5B in Q2 net income as COVID-19 drives down operating costs

By Paige Minemyer

Kaiser Permanente earned $4.5 billion in net income in the second quarter after a "challenging" Q1 as deferred procedures under the pandemic drove down operating costs.

PPD squeezes out a revenue growth despite COVID-19 disruption

By Ben Adams

Contract Research Organization PPD has seen its revenue nudge up in the second quarter as it navigates trial disruption while helping run one of the world’s most closely watched vaccine trials.

GigaGen’s polyclonal antibody against COVID-19 outperforms plasma in lab tests

By Arlene Weintraub

San Francisco startup GigaGen team took plasma from 50 COVID-19 survivors in Louisiana and used it to quickly create a polyclonal antibody to fight the disease. The antibody was 100 times more protective against the disease than convalescent plasma in lab tests and is headed to clinical trials early next year.

COVID-19 Tracker